340 related articles for article (PubMed ID: 26873056)
1. Comparison of AS03 and Alum on immune responses elicited by A/H3N2 split influenza vaccine in young, mature and aged BALB/c mice.
Yam KK; Gupta J; Allen EK; Burt KR; Beaulieu É; Mallett CP; Burt DS; Ward BJ
Vaccine; 2016 Mar; 34(12):1444-51. PubMed ID: 26873056
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Persistence of Cell-Mediated and Humoral Responses to A(H1N1)pdm09 Influenza Virus Vaccines and the Role of the AS03 Adjuvant System in Adults during Two Randomized Controlled Trials.
van der Most RG; Clément F; Willekens J; Dewé W; Walravens K; Vaughn DW; Leroux-Roels G
Clin Vaccine Immunol; 2017 Jun; 24(6):. PubMed ID: 28446441
[TBL] [Abstract][Full Text] [Related]
3. Effects of different adjuvants in the context of intramuscular and intranasal routes on humoral and cellular immune responses induced by detergent-split A/H3N2 influenza vaccines in mice.
Baz M; Samant M; Zekki H; Tribout-Jover P; Plante M; Lanteigne AM; Hamelin ME; Mallett C; Papadopoulou B; Boivin G
Clin Vaccine Immunol; 2012 Feb; 19(2):209-18. PubMed ID: 22190392
[TBL] [Abstract][Full Text] [Related]
4. Low hemagglutinin antigen dose influenza vaccines adjuvanted with AS03 alter the long-term immune responses in BALB/c mice.
Yam KK; Brewer A; Bleau V; Beaulieu É; Mallett CP; Ward BJ
Hum Vaccin Immunother; 2017 Mar; 13(3):561-571. PubMed ID: 27768511
[TBL] [Abstract][Full Text] [Related]
5. Long-term immunogenicity of an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine in young and elderly adults: an observer-blind, randomized trial.
Yang WH; Dionne M; Kyle M; Aggarwal N; Li P; Madariaga M; Godeaux O; Vaughn DW
Vaccine; 2013 Sep; 31(40):4389-97. PubMed ID: 23856331
[TBL] [Abstract][Full Text] [Related]
6. An observer-blind, randomized, multi-center trial assessing long-term safety and immunogenicity of AS03-adjuvanted or unadjuvanted H1N1/2009 influenza vaccines in children 10-17 years of age.
Poder A; Simurka P; Li P; Roy-Ghanta S; Vaughn D
Vaccine; 2014 Feb; 32(9):1121-9. PubMed ID: 24252703
[TBL] [Abstract][Full Text] [Related]
7. Analysis of the immunogenicity and bioactivities of a split influenza A/H7N9 vaccine mixed with MF59 adjuvant in BALB/c mice.
Ou H; Yao H; Yao W; Wu N; Wu X; Han C; Cheng L; Chen K; Chen H; Li L
Vaccine; 2016 Apr; 34(20):2362-70. PubMed ID: 27013436
[TBL] [Abstract][Full Text] [Related]
8. Randomized, multicenter trial of a single dose of AS03-adjuvanted or unadjuvanted H1N1 2009 pandemic influenza vaccine in children 6 months to <9 years of age: safety and immunogenicity.
Langley JM; Reich D; Aggarwal N; Connor D; Lebel MH; Gupta A; Garfield H; Li P; Madan A; Vaughn DW
Pediatr Infect Dis J; 2012 Aug; 31(8):848-58. PubMed ID: 22801094
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcome of the humoral and cellular immune response of an H5N1 adjuvanted influenza vaccine in elderly persons: 2-year follow-up of a randomised open-label study.
Gillard P; Giet D; Heijmans S; Dramé M; Walravens K; Roman F
Trials; 2014 Oct; 15():419. PubMed ID: 25354581
[TBL] [Abstract][Full Text] [Related]
10. Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial.
Jackson LA; Campbell JD; Frey SE; Edwards KM; Keitel WA; Kotloff KL; Berry AA; Graham I; Atmar RL; Creech CB; Thomsen IP; Patel SM; Gutierrez AF; Anderson EL; El Sahly HM; Hill H; Noah DL; Bellamy AR
JAMA; 2015 Jul; 314(3):237-46. PubMed ID: 26197184
[TBL] [Abstract][Full Text] [Related]
11. Squalene-adjuvanted H7N9 virus vaccine induces robust humoral immune response against H7N9 and H7N7 viruses.
Wu CY; Chang CY; Ma HH; Wang CW; Chen YT; Hsiao PW; Chang CC; Chan CH; Liu CC; Chen JR
Vaccine; 2014 Jul; 32(35):4485-4494. PubMed ID: 24962757
[TBL] [Abstract][Full Text] [Related]
12. Adjuvanted inactivated influenza A(H3N2) vaccines induce stronger immunogenicity in mice and confer higher protection in ferrets than unadjuvanted inactivated vaccines.
Ann J; Samant M; Rheaume C; Dumas C; Beaulieu E; Morasse A; Mallett C; Hamelin ME; Papadopoulou B; Boivin G
Vaccine; 2014 Sep; 32(43):5730-9. PubMed ID: 25173481
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and safety of an AS03-adjuvanted H7N1 vaccine in healthy adults: A phase I/II, observer-blind, randomized, controlled trial.
Madan A; Ferguson M; Sheldon E; Segall N; Chu L; Toma A; Rheault P; Friel D; Soni J; Li P; Innis BL; Schuind A
Vaccine; 2017 Mar; 35(10):1431-1439. PubMed ID: 28187952
[TBL] [Abstract][Full Text] [Related]
14. Safety and persistence of the humoral and cellular immune responses induced by 2 doses of an AS03-adjuvanted A(H1N1)pdm09 pandemic influenza vaccine administered to infants, children and adolescents: Two open, uncontrolled studies.
Garcia-Sicilia J; Arístegui J; Omeñaca F; Carmona A; Tejedor JC; Merino JM; García-Corbeira P; Walravens K; Bambure V; Moris P; Caplanusi A; Gillard P; Dieussaert I
Hum Vaccin Immunother; 2015; 11(10):2359-69. PubMed ID: 26176592
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months.
Carmona A; Omeñaca F; Tejedor JC; Merino JM; Vaman T; Dieussaert I; Gillard P; Arístegui J
Vaccine; 2010 Aug; 28(36):5837-44. PubMed ID: 20600478
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of AS03-adjuvanted and non-adjuvanted trivalent inactivated influenza vaccines in elderly adults: A Phase 3, randomized trial and post-hoc correlate of protection analysis.
Ruiz-Palacios GM; Leroux-Roels G; Beran J; Devaster JM; Esen M; Launay O; McElhaney JE; van Essen GA; Benoit A; Claeys C; Dewé W; Durand C; Duval X; Falsey AR; Feldman G; Galtier F; Gervais P; Hwang SJ; McNeil S; Richardus JH; Trofa A; Oostvogels L;
Hum Vaccin Immunother; 2016 Dec; 12(12):3043-3055. PubMed ID: 27690762
[TBL] [Abstract][Full Text] [Related]
17. Obesity Outweighs Protection Conferred by Adjuvanted Influenza Vaccination.
Karlsson EA; Hertz T; Johnson C; Mehle A; Krammer F; Schultz-Cherry S
mBio; 2016 Aug; 7(4):. PubMed ID: 27486196
[TBL] [Abstract][Full Text] [Related]
18. Administration of AS03B-adjuvanted A(H1N1)pdm09 vaccine in children aged <3 years enhances antibody response to H3 and B viruses following a single dose of trivalent vaccine one year later.
Hoschler K; Andrews NJ; Faust SN; Finn A; Pollard AJ; Snape MD; Walker WT; Zambon M; Miller E
Clin Infect Dis; 2014 Jan; 58(2):181-7. PubMed ID: 24149079
[TBL] [Abstract][Full Text] [Related]
19. Long-term persistence of humoral and cellular immune responses induced by an AS03A-adjuvanted H1N1 2009 influenza vaccine: an open-label, randomized study in adults aged 18-60 years and older.
Van Damme P; Kafeja F; Bambure V; Hanon E; Moris P; Roman F; Gillard P
Hum Vaccin Immunother; 2013 Jul; 9(7):1512-22. PubMed ID: 23571166
[TBL] [Abstract][Full Text] [Related]
20. Humoral response to the influenza A H1N1/09 monovalent AS03-adjuvanted vaccine in immunocompromised patients.
Manuel O; Pascual M; Hoschler K; Giulieri S; Alves D; Ellefsen K; Bart PA; Venetz JP; Calandra T; Cavassini M
Clin Infect Dis; 2011 Jan; 52(2):248-56. PubMed ID: 21288852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
